依达拉奉注射液联合Rho激酶抑制剂对急性脑梗死患者神经功能及血清ENA-78、HMGB1水平的影响  

Effects of edaravone injection combined with Rho kinase inhibitor on neurological function and serum ENA-78,HMGB1 levels in patients with acute cerebral infarction

作　　者：郭云飞 Guo Yurifei(The Second People's Hospital of Datong,Datong 037000,China)

机构地区：[1]山西省大同市第二人民医院,037000

出　　处：《中国实用医刊》2019年第2期111-115,共5页Chinese Journal of Practical Medicine

摘　　要：目的探讨依达拉奉注射液联合Rho激酶抑制剂法舒地尔对急性脑梗死患者神经功能及血清中性粒细胞激活肽-78(ENA-78)、高迁移率族蛋白1(HMGB1)水平的影响。方法选取大同市第二人民医院2015年12月至2018年3月急性脑梗死患者86例,随机分为两组,每组43例。对照组采用依达拉奉治疗,研究组在对照组基础上加用Rho激酶抑制剂(法舒地尔)治疗,均治疗2周。比较两组治疗前及疗程结束后日常生活能力(BI)及神经功能缺损(NIHSS)评分、临床疗效、治疗前及疗程结束后血清ENA-78及HMGB1水平、神经生长因子(NGF)、脑源性神经营养因子(BDNF)水平、不良反应发生率。结果疗程结束后两组NIHSS、BI分值较治疗前改善,且研究组BI分值高于对照组,NIHSS分值低于对照组(P<0.05);研究组总有效率(90.70%)高于对照组(74.42%,P<0.05);疗程结束后研究组血清ENA-78及HMGB1水平低于对照组,BDNF、NGF水平高于对照组(P<0.05);研究组不良反应发生率(13.95%)与对照组(9.30%)比较差异未见统计学意义(P>0.05)。结论依达拉奉注射液联合Rho激酶抑制剂法舒地尔治疗急性脑梗死患者,可有效降低血清ENA-78及HMGB1水平,提高BDNF及NGF含量,促进患者神经功能及日常生活能力恢复,提高疾病治疗效果,且不会增加不良反应发生风险,具有一定安全性。Objective To investigate the effects of edaravone injection combined with Rho kinase inhibitor fasudil on neurological function and serum levels of neutrophil activating peptide 78(ENA-78)and high mobility group protein 1(HMGB1)in patients with acute cerebral infarction.Methods Eighty-six patients with acute cerebral infarction in the Second People’s Hospital of Datong from December 2015 to March 2018 were enrolled.The patients were randomly divided into two groups,with 43 cases in each group.Edaravone was used in the control group,and the study group was treated with Rho kinase inhibitor(fasudil)on the basis of the treatment in the control group,and both the two groups were treated for 2 weeks.The daily living ability(BI)and neurological deficit(NIHSS)scores,clinical efficacy,serum ENA-78 and HMGB1 levels,nerve growth factor(NGF),brain-derived neurotrophic factor(BDNF)and the incidences of adverse reactions were compared.Results After treatment,the NIHSS and BI scores of the two groups were improved in comparison with those before treatment,and the BI score of the study group was higher than that of the control group,and the NIHSS score was lower than that of the control group(P<0.05).The total effective rate of the study group(90.70%)was higher than that of the control group(74.42%,P<0.05).After treatment,the serum levels of ENA-78 and HMGB1 in the study group were lower than those in the control group,and the levels of BDNF and NGF were higher than those in the control group(P<0.05);there was no significant difference in the incidence of adverse reactions between the study group(13.95%)and the control group(9.30%,P>0.05).Conclusions Edaravone injection combined with Rho kinase inhibitor fasudil for acute cerebral infarction can effectively reduce the serum ENA-78 and HMGB1 levels,increase the BDNF and NGF levels,and promote the neurological function and daily living ability.It can improve the therapeutic effect of the disease,and does not increase the risk of adverse reactions,and has a certain degree of saf

关 键 词：依达拉奉注射液 RHO激酶抑制剂 急性脑梗死 神经功能 中性粒细胞激活肽 高迁移率族蛋白1 

分 类 号：R743.3[医药卫生—神经病学与精神病学]